In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China

References

• Bitar D, Lortholary O, Le Strat Y, et al. Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010. Emerg Infect Dis. 2014;20(7):1149–1155. doi:10.3201/eid2007.140087
   PubMed Web of Science ®Google Scholar
• Donnelley MA, Zhu ES, Thompson GR. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infect Drug Resist. 2016;9:79–86.
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16(1):730.
   PubMed Web of Science ®Google Scholar
• Farmakiotis D, Kontoyiannis DP. Mucormycoses. Infect Dis Clin North Am. 2016;30(1):143–163.
   PubMed Web of Science ®Google Scholar
• Meis JF, Chakrabarti A. Changing epidemiology of an emerging infection: zygomycosis. Clin Microbiol Infect. 2009;15 Suppl 5:10–14.
   Web of Science ®Google Scholar
• Prakash H, Chakrabarti A. Global Epidemiology of Mucormycosis. J Fungi. 2019;5(1):457.
   Web of Science ®Google Scholar
• Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44:335–342.
   PubMed Web of Science ®Google Scholar
• Liao Y, Chen M, Hartmann T, Yang RY, Liao WQ. Epidemiology of opportunistic invasive fungal infections in China: review of literature. Chin Med J. 2013;126:361–368.
   Web of Science ®Google Scholar
• Patterson TF, Thompson GR, Denning DW, et al. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1–e60.
   PubMed Web of Science ®Google Scholar
• ECDC. European Centre for Disease Prevention and Control. Risk assessment on the impact of environmental usage of triazoles on the development and spread of resistance to medical triazoles in Aspergillus species; 2013. Available from: https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/risk-assessment-impact-environmental-usage-of-triazoles-on-Aspergillus-spp-resistance-to-medical-triazoles.pdf. Accessed September 13, 2021.
   Google Scholar
• van der Linden JW, Arendrup MC, Warris A, et al. Prospective Multicenter International Surveillance of Azole Resistance in Aspergillus fumigatus. Emerg Infect Dis. 2015;21(6):1041–1044. doi:10.3201/eid2106.140717
   PubMed Web of Science ®Google Scholar
• Dannaoui E. Antifungal resistance in mucorales. Int J Antimicrob Agents. 2017;50(5):617–621.
   PubMed Web of Science ®Google Scholar
• Personett HA, Kayhart BM, Barreto EF, et al. Renal Recovery following Liposomal Amphotericin B-Induced Nephrotoxicity. Int J Nephrol. 2019;2019:8629891.
   PubMed Web of Science ®Google Scholar
• EMA. Cresemba; 2021. Available form: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba;. Accessed June. 2021.
   Google Scholar
• Drug Trials USFDA. Snapshots: CRESEMBA (aspergillosis); 2020. Available form: https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-cresemba-aspergillosis. Accessed April 15, 2022.
   Google Scholar
• Guillen Vera D, Ruiz Ruigómez M, García Moguel I, Morales Ruiz R, Corbella L, Fernández Rodríguez C. Successful Treatment of Chronic Pulmonary Aspergillosis With Isavuconazole. J Investig Allergol Clin Immunol. 2019;29(6):459–460.
   Web of Science ®Google Scholar
• McCarthy MW, Moriyama B, Petraitiene R, Walsh TJ, Petraitis V. Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole. Clin Pharmacokinet. 2018;57(12):1483–1491.
   Web of Science ®Google Scholar
• CLSI. Clinical and Laboratory Standards Institute. M38 Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. Available from. https://clsi.org/media/1894/m38ed3_sample.pdf. Accessed April 15, 2022.
   Google Scholar
• CLSI. Clinical and Laboratory Standards Institute. M61 (Ed2), Performance Standards for Antifungal Susceptibility Testing of Filamentous Fungi. Available from: https://clsi.org/standards/products/microbiology/documents/m61/. Accessed March 15, 2022.
   Google Scholar
• Nelson DR. The Cytochrome P450 Homepage. Hum Genomics. 2009;4(1):59.
   PubMedGoogle Scholar
• Espinel-Ingroff A, Chakrabarti A, Chowdhary A, et al. Multicenter evaluation of MIC distributions for epidemiologic cutoff value definition to detect amphotericin B, posaconazole, and itraconazole resistance among the most clinically relevant species of Mucorales. Antimicrob Agents Chemother. 2015;59(3):1745–1750.
   PubMed Web of Science ®Google Scholar
• CLSI. Clinical and Laboratory Standards Institute. M59, Epidemiological cutoff values for antifungal susceptibility testing. Available from: https://clsi.org/media/1934/m59ed2_sample-updated.pdf. Accessed August 2021.
   Google Scholar
• Chau AS, Chen G, McNicholas PM, Mann PA. Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob Agents Chemother. 2006;50:3917–3919.
   PubMed Web of Science ®Google Scholar
• Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother. 2006;57:1235–1239.
   PubMed Web of Science ®Google Scholar
• Rudramurthy SM, Paul RA, Chakrabarti A, Mouton JW, Meis JF. Invasive Aspergillosis by Aspergillus flavus: epidemiology, Diagnosis, Antifungal Resistance, and Management. J Fungi. 2019;5(55):1–33.
   Google Scholar
• Ashu EE, Korfanty GA, Samarasinghe H, et al. Widespread amphotericin B-resistant strains of Aspergillus fumigatus in Hamilton, Canada. Infect Drug Resist. 2018;11:1549–1555.
   PubMed Web of Science ®Google Scholar
• Alvarez E, Sutton DA, Cano J, et al. Spectrum of zygomycete species identified in clinically significant specimens in the United States. J Clin Microbiol. 2009;47:1650–1656.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405–e421.
   PubMed Web of Science ®Google Scholar
• Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26–34.
   PubMed Web of Science ®Google Scholar
• Badali H, Cañete-Gibas C, McCarthy D, et al. Epidemiology and Antifungal Susceptibilities of Mucoralean Fungi in Clinical Samples from the United States. J Clin Microbiol. 2021;59:e01230–21.
   Web of Science ®Google Scholar
• Gong Y, Li C, Wang C, et al. Epidemiology and Mortality-Associated Factors of Invasive Fungal Disease in Elderly Patients: a 20-Year Retrospective Study from Southern China. Infect Drug Resist. 2020;13:711–723.
   Web of Science ®Google Scholar
• Alanio A, Dellière S, Fodil S, Bretagne S, Mégarbane B. Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. Lancet Resp Med. 2020;8(6):e48–e49.
   PubMed Web of Science ®Google Scholar
• van Arkel ALE, Rijpstra TA, Belderbos HNA, van Wijngaarden P, Verweij PE, Bentvelsen RG. COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132–135.
   PubMed Web of Science ®Google Scholar
• Wang J, Yang Q, Zhang P, Sheng J, Zhou J, Qu T. Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: a retrospective case series. Crit Care. 2020;24(1):299.
   PubMed Web of Science ®Google Scholar
• Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-Associated Pulmonary Aspergillosis, March-August 2020. Emerg Infect Dis. 2021;27:1077–1086.
   PubMed Web of Science ®Google Scholar
• Pasero D, Sanna S, Liperi C, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. Infection. 2020;1:45. doi:10.1007/s15010-020-01561-x
   Web of Science ®Google Scholar
• Li Y, Wang H, Hou X, Huang -J-J, Wang P-C, Xu Y-C. Identification by Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry and Antifungal Susceptibility Testing of Non-Aspergillus Molds. Front Microbiol. 2020;11:922.
   Web of Science ®Google Scholar
• Wiederhold NP. Antifungal resistance: current trends and future strategies to combat. Infect Drug Resist. 2017;10:249–259.
   PubMed Web of Science ®Google Scholar
• Lanternier F, Poiree S, Elie C, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. J Antimicrob Chemother. 2015;70:3116–3123.
   PubMed Web of Science ®Google Scholar
• Arendrup Maiken CJR. In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order. Antimicrob Agents Chemother. 2015;59(12):7735–7742.
   Web of Science ®Google Scholar
• Caramalho R, Monk BC, Larentis T, Lass-Flörl C, Lackner M. Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase. Sci Rep. 2017;7:15898.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Singh PK, Kathuria S, Hagen F, Meis JF. Comparison of the EUCAST and CLSI Broth Microdilution Methods for Testing Isavuconazole, Posaconazole, and Amphotericin B against Molecularly Identified Mucorales Species. Antimicrob Agents Chemother. 2015;59:7882–7887.
   PubMed Web of Science ®Google Scholar